"approved"@en . . . "Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, \"Mometasone furoate monohydrate, process for making same and pharmaceutical compositions.\" U.S. Patent US6127353, issued April, 1988."@en . . . . "Mometason"@en . . . . . "Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone."@en . "Nasal spray is virtually undetectable in plasma"@en . . "Mom\u00E9tasone (furoate de)"@en . . . . . . . . "5.8 hours"@en . . . . . . . "Mometasona"@en . . . . . . . . . . . . . . . . . "Mometasoni furoas "@en . . . . . . . . . "Humans and other mammals"@en . "Mometasonfuroat "@en . . "Mometasone Furoate"@en . . . . . . "The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis."@en . . . . . "Mometasone"@en . "The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Mom\u00E9tasone"@en . . . . . . . . . . . . . . . . . . "(+)-Mometasone"@en . . . "Mometasonum"@en . . . "Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes."@en . . "105102-22-5"@en . . . . . . . . . . "Mometasone Furoate Hydrate"@en . . . . . "Mometason furoat-1-Wasser"@en . . "98% to 99% (in a concentration range of 5 to 500 ng/mL)."@en . . . .